Highlighting Recent Advancements During Psoriasis Action Month

Image Credit: © SergeVo - stock.adobe.com

With over 125 million patients worldwide who have psoriasis and manage its symptoms daily, 1 month isn’t enough to address all updates, advancements, and future directions.¹ However, this month allows clinicians and patients to slow down, reflect on how far treatments have come, and look ahead to how patients’ lives can continue to be improved.

This Psoriasis Action Month, we take a deep dive into rethinking systemic eligibility, how to properly treat pediatric patients with moderate to severe psoriasis, and how to use case studies to improve your practice.

Dermatology Times’ editor in chief, Christopher G. Bunick, MD, PhD, addresses the evolving understanding of moderate psoriasis and how systemic therapies can be used earlier than previously thought. In his letter, Bunick reviews data that consider PDE4 inhibitors vs JAK inhibitors for moderate psoriasis, as well as upcoming therapies to look forward to, including zasocitinib (Takeda), a selective TYK2 inhibitor, and icotrokinra (Protagonist and Janssen), a first-in-class oral IL-23 receptor antagonist.

In this month’s cover feature, Karan Lal, DO, MS, reviews his top pearls for treating pediatric patients with moderate to severe psoriasis, especially when considering comorbidities and symptoms.

Don’t miss other crucial content from Tatjana Pavicic, MD, PhD; Frank Lin, MBBS; Julieta Spada, MD; Jennifer Levine, MD; and Matthew Jackson, PhD, on microfocused ultrasound with visualization for skin quality.

The Dermatology Times team is returning from a busy month of travel after covering the Dermatology Education Foundation DERM2025 NP/PA Conference in Las Vegas, Nevada; the Elevate-Derm Summer 2025 Conference in Park City, Utah; and the Society for Pediatric Dermatology 2025 Annual Meeting in Seattle, Washington. Look for next month’s issue for conference highlights and scan the QR code to the right to see recent online news.

As always, Dermatology Times delivers the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert perspectives. Stay informed with the latest data—subscribe to Dermatology Times’ e-newsletters and follow us on Facebook, LinkedIn, and X.

Mike Hennessy Jr

Mike Hennessy Jr

Chairman and CEO
MJH Life Sciences

Reference

1. Psoriasis Action Month is here. National Psoriasis Foundation. Updated August 1, 2024. Accessed July 16, 2025. https://www.psoriasis. org/advance/psoriasis-action-month-here/